Co-Diagnostics files FDA 510(k) for flu and RSV PCR test
The molecular diagnostics company's concurrent CLIA Waiver by Application, if granted, would allow testing in decentralised point-of-care settings.
The molecular diagnostics company's concurrent CLIA Waiver by Application, if granted, would allow testing in decentralised point-of-care settings.